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Objective To evaluate the pathogenicity of Dientamoeba fragilis by comparing it with
Giardia lamblia and to investigate the effect of a single dose of secnidazole in dienta-
moebiasis.
Methods Stool samples of 400 patients, admitted to the Department of Parasitology, Celal
Bayar University, were examined by direct wet mount, formalin–ethyl acetate concen-
tration and trichrome staining methods on three consecutive days. All cases positive for
D. fragilis were treated with a single dose of secnidazole, 30 mg/kg for children, and 2 g
for adults. On the seventh and fourteenth days, at the end of the treatment, stool samples
were examined by the same methods, and clinical symptoms were again evaluated.
Results D. fragilis and G. lamblia were detected in 35 (8.8%) and 34 (8.5%) cases,
respectively. The most frequent symptoms were found to be abdominal pain and
diarrhea in both infections. D. fragilis was eradicated in 34 (97.1%) patients with a single
dose of secnidazole, but a second dose was necessary in one patient. Clinical symptoms
disappeared in 27 (77.1%) and decreased in eight (22.9%) cases, after eradication.
Conclusions These data suggested that D. fragilis is as prevalent and pathogenic as G.
lamblia, and secnidazole seems to be highly effective in achieving parasitologic and
clinical cure. To our knowledge, this is the first report of secnidazole being used in the
treatment of dientamoebiasis.
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I N T R O D U C T I O N
The pathogenicity of Dientamoeba fragilis has been
debated for many years. Today, clinical symptoms
such as abdominal pain, diarrhea, anorexia, nau-
sea, vomiting and flatulence, which usually dis-
appear with the elimination of the parasite, are
reported to be associated with D. fragilis [1–4].
Secnidazole, a 5-nitroimidazole, has a long half-
life (approximately 17–29 h), and therefore has
been used as single-dose therapy in giardiasis,
trichomoniasis, amebiasis and bacterial vaginosis
[5,6].
The objective of this study was to evaluate the
frequency and the pathogenicity of D. fragilis by
comparing it with Giardia lamblia, a better-known
parasite. The effect of a single dose of secnidazole
on D. fragilis was also investigated.
M A T E R I A L S A N D M E T H O D S
Stool samples of 400 patients admitted to the
Department of Parasitology, Celal Bayar Univer-
sity, were investigated for intestinal parasites three
times on consecutive days. Only fresh stool speci-
mens (within 30 min of passage) were accepted,
and were immediately fixed in both Schaudinn’s
fixative and 10% formalin solution. All samples
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were examined by direct wet smear, trichrome
staining (Wheatley modification), and formalin–
ethyl acetate concentration procedures, as pre-
viously described [7].
A questionnaire was completed for each case,
concerning clinical symptoms (duration and sev-
erity, if any). Stool samples were examined macro-
scopically. At least three soft or liquid stools per
day are considered to constitute diarrhea, and one
formed stool a day is regarded as disappearance
of this symptom. Thirty-two cases with only D.
fragilis and three patients with both D. fragilis and
G. lamblia infections were treated with a single
dose of secnidazole after dinner, 2 g for adults
and 30 mg/kg for children 3–15 years of age. This
treatment was ineffective in only one adult patient,
and the same dose of secnidazole was repeated in
this case. On the seventh and fourteenth days, at
the end of the treatment, stool samples were exam-
ined by the same methods, and clinical symptoms
were again evaluated; patients did not receive any
other drugs for one week before and two weeks
after the secnidazole treatment.
Adult patients and parents of the children were
informed about the study, and written consents
were obtained. The research was approved by the
Ethics Committee of the Faculty of Medicine, Celal
Bayar University, in accordance with the Helsinki
Declaration.
Comparisons were performed by chi-square
tests (Yates corrected).
R E S U L T S
Four hundred cases aged between 2 and 60 years
(mean¼ 21.6 15.0) were examined for intestinal
parasites. Of these cases, 35 (8.8%) patients, aged
between 3 and 60 years (mean¼ 16.9 11.7), were
positive for D. fragilis, and 34 (8.5%) patients, aged
between 4 and 55 years (mean¼ 14.7 11.0), were
positive for G. lamblia. Entamoeba histolytica, Hyme-
nolepis nana and Taenia saginata were detected in
six cases (1.5%), two cases (0.5%), and one (0.3%)
case, respectively. The only pathogenic parasite
was D. fragilis in 32 patients, and G. lamblia in 30
patients. Among all cases, the infection rates were
found to be significantly (P< 0.05) higher in the 8–
15-year age group for dientamoebiasis (14.8%),
and in the 8–15- and 0–7-year age groups (13.0%
and 12.7%, respectively) for giardiasis.
D. fragilis trophozoites could only be detected by
trichrome-stained slides in all cases. However, wet
smear and/or formalin–ethyl acetate concentra-
tion methods were found to be effective in detect-
ing 33 of 34 cases positive for G. lamblia. Of the 35
cases positive for D. fragilis, 30 were detected in the
first, three in the second, and two in the third stool
examination.
The most frequent symptoms were found to be
abdominal pain (81.3%) and diarrhea (71.9%) in
patients with only dientamoebiasis. These two
symptoms were found to be significantly more
frequent in patients with either only dientamoe-
biasis or only giardiasis, when compared to cases
with no pathogenic parasites (P< 0.001). Clinical
symptoms in patients with only D. fragilis infec-
tion, only G. lamblia infection and no pathogenic
parasites are shown in Table 1.
Follow-up controls showed that D. fragilis was
eradicated in 31 of 32 patients with only dienta-
moebiasis, and in all three cases with both D.
fragilis and G. lamblia infection, after a single dose
of secnidazole, but a second dose was needed for
eradication of D. fragilis in one patient. Of the 32
cases with only D. fragilis infection, clinical symp-
toms disappeared after eradication of the parasite
in 16 of 18 children (88.9%), and in nine of 14 adults
(64.3%), while they decreased in two children
(11.1%) and five adults (35.7%). In total, clinical
cure and decreases in symptoms were observed in
25 (78.1%) and seven (21.9%) cases, respectively.
No side effects were observed, except for mild
nausea in two patients.
D I S C U S S I O N
Although previously considered harmless, D. fra-
gilis has been associated with a variety of symp-
toms, mainly diarrhea and abdominal pain [1–4].
In this study, abdominal pain and diarrhea were
Table 1 Clinical symptoms in cases with only D. fragilis,
only G. lamblia, and no pathogenic parasite
Symptoms
Only
D. fragilis
(n¼ 32)
n (%)
Only
G. lamblia
(n¼ 30)
n (%)
No pathogenic
parasite
(n¼ 326)
n (%)
Abdominal pain 26 (81.3) 21 (70.0) 63 (19.3)
Diarrhea 23 (71.9) 23 (76.7) 37 (11.3)
Anorexia 5 (15.6) 2 (6.7) 34 (10.4)
Fatigue 3 (9.4) 3 (10.0) 30 (9.2)
Nausea 2 (6.3) 2 (6.7) 20 (6.1)
Weight loss 1 (3.1) 2 (6.7) 16 (4.9)
Vomiting 1 (3.1) 1 (3.3) 16 (4.9)
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found to be significantly more frequent in patients
with only dientamoebiasis than in cases with no
pathogenic parasite (P< 0.001). No significant dif-
ferences were observed between cases with only
dientamoebiasis and those with only giardiasis for
these two symptoms. These data represent strong
evidence for the pathogenicity of D. fragilis.
The incidence of D. fragilis infection has been
reported from different areas of the world in a
wide range from 1.4% to 52% [1–3, 8]. The organ-
ism was reported to be the most common enter-
opathogenic parasite in the Sultanate of Oman [9]
and in US soldiers stationed in Egypt [10]. The low
incidence or absence of this organism in different
surveys may be due to the use of poor laboratory
recovery techniques and/or a general lack of
knowledge concerning the parasite. Considerably
higher incidences of D. fragilis infection were
reported among children than among adults
[1,8]. In this study, the infection rate was found
to be significantly (P< 0.05) higher only in the 8–
15-year age group. Among our 400 cases, D. fragilis
was the most frequently detected parasite, being
detected in 35 cases (8.8%), while G. lamblia and E.
histolytica were detected in 34 (8.5%) and six (1.5%)
cases, respectively. The frequencies of these para-
sites were probably higher than their incidences in
society, because all of our cases were admitted to
the Department of Parasitology due to symptoms
suggesting parasitic infections.
The diagnosis of dientamoebiasis depends on
the demonstration of the parasite, which typically
has two (or sometimes one) nuclei, each containing
4–6 granules. It is reported that a permanent stain
such as trichrome or iron hematoxylin is obliga-
tory in the diagnosis of D. fragilis, and experience
and attention are also required, even when these
stains are performed [1–3,7,8]. D. fragilis tropho-
zoites could only be detected by trichrome-stained
slides in all of our cases, whereas direct wet smear
and formalin–ethyl acetate concentration proce-
dures were found to be completely useless for
the recovery of this organism. Of the 35 cases,
three were detected in the second and two in the
third stool examination. These findings suggest
that a staining method such as trichrome should
be applied to every stool sample, and at least three
stool examinations should be performed before
concluding that no parasite is present.
Diiodohydroxyquin, tetracycline, metronidazole
and paromomycin were previously used for the
treatment of D. fragilis infection, and the duration
of these treatments is between five and 21 days
[2,3]. Secnidazole has the advantage of having a
long half-life, which makes possible the single-
dose application [5,6]. As with other nitroimida-
zoles, the antiprotozoal activity of secnidazole is
linked to the ferrodoxin oxidoreductase-mediated
reduction of the nitro group, which cannot occur
under aerobic conditions. Therefore, secnidazole is
toxic only for anaerobic organisms such as G.
lamblia, E. histolytica, and Trichomonas vaginalis [6].
A single dose of secnidazole was found to be
effective for the eradication of D. fragilis in all of
our patients, except for one who needed a second
identical dose. This patient was a 55-year-old male
with diarrhea and abdominal pain. His symptoms
and excretion of D. fragilis trophozoites continued
after the first treatment with secnidazole, but dis-
appeared on the seventh and fourteenth days of
the second treatment. After eradication of D. fra-
gilis, the symptoms disappeared in 16 of 18 (88.9%)
children and nine of 14 (64.3%) adults, and
decreased in all other cases. The high correlation
between eradication of D. fragilis and the disap-
pearance or decrease in clinical symptoms sug-
gested that D. fragilis is responsible for these.
Secnidazole was used after dinner, to reduce the
riskofnauseaandvomiting,andnosideeffectswere
observed, except for mild nausea in two patients.
These data suggested that D. fragilis is a com-
mon parasite and causes clinical symptoms as
frequently as G. lamblia. Secnidazole may be a
novel drug in the treatment of dientamoebiasis,
with its easy single-dose application and high
effectiveness. To our knowledge, this is the first
time that secnidazole has been used in the treat-
ment of D. fragilis infection. More studies are
needed to evaluate the efficacy of different agents
against this parasite.
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